{"id":504628,"date":"2020-08-28T13:18:01","date_gmt":"2020-08-28T13:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=504628"},"modified":"2020-08-28T13:18:01","modified_gmt":"2020-08-28T13:18:01","slug":"nonmuscle-invasive-bladder-cancer-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonmuscle-invasive-bladder-cancer-market-size-share-trends-epidemiology-forecast-till-2030_504628.html","title":{"rendered":"Non-Muscle Invasive Bladder Cancer Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"
\"Non-Muscle<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Non-Muscle Invasive Bladder Cancer (NMIBC), historical and forecasted epidemiology as well as the Non-Muscle Invasive Bladder Cancer (NMIBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Non-Muscle Invasive Bladder Cancer (NMIBC) is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.<\/p>\n

 <\/p>\n

Non-Muscle Invasive Bladder Cancer Market Insight<\/strong><\/p>\n

The market size of Non-Muscle Invasive Bladder Cancer in 7MM in 2017 was USD 1,454 Million  <\/a><\/strong><\/p>\n

 <\/p>\n

NMIBC remains a very challenging disease to treat with high rates of recurrence and progression associated with current therapies. The high rates of progression and recurrence with current therapies for NMIBC necessitate lifelong active surveillance, making bladder cancer the most expensive cancer to treat from diagnosis to death, as well as driving the need for the development of new therapies in patients with NMIBC.<\/p>\n

 <\/p>\n

The current treatment regimen include surgery, intravesical immunotherapy (BCG) and intravesical chemotherapy. Intermediate- or high-risk NMIBC is generally treated with transurethral resection of bladder tumor (TURBT), followed by adjuvant BCG immunotherapy which is the gold standard treatment for reducing tumor recurrence rates and preventing subsequent stage progression. Stage 0 bladder cancer is most often treated with TURBT with fulguration followed by intravesical therapy within 24 h. Sometimes no further treatment is needed. Cystoscopy is then done every 3–6 months to watch for signs that cancer has come back.<\/p>\n

In addition to this, there is only one approved drug for the treatment of NMIBC namely Keytruda (pembrolizumab) which is approved for the treatment of patients with BCG-unresponsive, high-risk, NMIBC with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.<\/p>\n

There are two types of intravesical therapy, namely immunotherapy and chemotherapy. BCG is the most common intravesical immunotherapy for treating early-stage bladder cancer. It is used to help keep cancer from growing, prevents it from relapse. BCG is a germ that is related to the one that causes tuberculosis (TB), but it does not usually cause serious disease.<\/p>\n

Non-Muscle Invasive Bladder Cancer Market Drivers<\/a><\/strong><\/p>\n